The US Food and Drug Administration (FDA) has approved the injectable antibiotics Piperacillin and Tazobactam for use in B Braun Medical’s Duplex drug delivery system.
The drug delivery system is a ready-to-activate container that separates pre-measured medication and diluent until activation by the provider during treatment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The system decreases process time by around four minutes for each dose and saves considerable labour time in comparison to the Baxter Mini-Bag Plus container system and traditional compounding methods.
B Braun’s Duplex system is engineered to minimise risks of contamination and medication errors.
Its closed-system design protects the potency of the drug and ensures that the diluent cannot be administered without the medication.
With fewer process steps, the system has been shown to decrease the possibility of medication errors by 54% versus traditional compounding.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe system eliminates the need for thawing and is suitable for storage at room temperature or in automated dispensing cabinets.
B Braun medical marketing senior director Jeremy Greene stated: “We are excited to introduce Piperacillin and Tazobactam in our innovative Duplex drug delivery system, designed to save time, labour and space, and reduce waste.
“Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve.”
This is B Braun’s second introduction of antibiotics into the drug delivery system in 2025, following the launch of Cefazolin 3g, and is part of the company’s strategy to expand its portfolio of injectable drugs in the US.
Headquartered in Pennsylvania, the company specialises in pharmacy products and infusion therapy.
